ArticlemBio2026
Emergence of vaccine-derived poliovirus strains from the novel oral polio vaccine in the Central African Republic.
Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The Central African Republic (CAR) is a high-risk country for poliomyelitis outbreaks because of difficulties in closing immunity gaps due to the lack of resources, logistics issues, and insecurity. The country experienced multiple poliomyelitis cases since 2019. A novel type 2 oral polio vaccine (nOPV2) engineered to lower the risk of reversion of the vaccine strain was deployed in the CAR in 2022-2023 to counter active serotype 2 poliovirus transmission. This study reports routine poliovirus surveillance conducted from November 2021 through October 2023 in the CAR. Polioviruses isolated from stools and wastewater were genetically characterized based on the VP1-encoding region that was sequenced by Sanger technique. Whole-genome sequencing was conducted on all nOPV2-derived isolates and on a subset of Sabin-2-derived isolates by using Illumina technology. Fifty-four vaccine-derived poliovirus type 2 isolates were identified, belonging to eight distinct emergences: four emergences were derived from the historical vaccine strain and four from the nOPV2. The nOPV2 derivatives that had kept the original 5' untranslated region (5'UTR) did not display any reversions in the modified domain V, which is the primary attenuation site. Nonetheless, some nOPV2 derivatives had lost this domain through recombination with members of species IMPORTANCE: The novel oral polio vaccine of serotype 2 (nOPV2) was engineered to prevent the emergence of revertant polio vaccine strains, which caused numerous outbreaks in the 2000s and 2010. Since 2021, it has been used in many countries, especially in Sub-Saharan Africa, to contain poliomyelitis outbreaks. In 2023, double recombinant nOPV2-derived isolates that had lost all the attenuation determinants were detected in the Central African Republic (CAR). Several of these were the first nOPV2 revertant isolates ever reported to the Global Polio Eradication Initiative, thereby demonstrating that the engineered modifications in nOPV2 do not entirely prevent reversion via recombination with non-polio enteroviruses of species
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.